Chimeric Antigen Receptor (CAR) T-Cell Therapy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 

Chimeric Antigen Receptor (CAR) T-cell therapy is an advanced immunotherapy used to treat certain types of cancer. It involves genetically modifying a patient's T-cells to express a chimeric antigen receptor on their surface, allowing them to recognize and attack cancer cells expressing specific antigens. The CAR T-cell therapy process includes the following:

1. Collection of T-cells from the patient's blood through leukapheresis.
2. Genetic engineering of T-cells in the lab using a viral vector to introduce the CAR gene.
3. Expansion of genetically modified T-cells to produce a large number of CAR T-cells.
4. Infusion of the CAR T-cells back into the patient's bloodstream.
5. Targeting and destruction of cancer cells by activated CAR T-cells.

The market for CAR T-cell therapy has been rapidly growing due to its high success rates in treating blood cancers and its potential in other malignancies. Pharmaceutical and biotech companies have invested significantly in developing CAR T-cell therapies and conducting clinical trials to expand their scope. EMA and FDA have approved CAR T-cell therapies for different indications. Tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta) were the first CAR T-cell therapies to receive approval for certain forms of leukemia and lymphoma.

Thelansis’s “Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chimeric Antigen Receptor (CAR) T-Cell Therapy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Chimeric Antigen Receptor (CAR) T-Cell Therapy across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Chimeric Antigen Receptor (CAR) T-Cell Therapy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033